HIGHLIGHTS
- who: Hanyue Xu from the (UNIVERSITY) have published the research: Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials, in the Journal: (JOURNAL)
- how: These results indicated that DS-8201a had durable antitumor activity to HER2-positive cancer especially breast cancer.
- future: More studies are required for exploring the ability of DS8201a using alone or in combination with other drugs and finding methods to reduce AEs.
SUMMARY
Human epidermal growth factor receptor 2 (HER2) is one of the epidermal growth factor transmembrane . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.